Imperva Announces First Quarter 2015 Financial Results

Go back to Imperva Announces First Quarter 2015 Financial Results

Needham & Company Raises PT Sharply as Imperva (IMPV) Raises Guidance

May 8, 2015 6:59 AM EDT

Needham & Company reiterates their Buy rating on Imperva, Inc. (NYSE: IMPV), and raised the price target to $67 (from $48), after a strong, and well above consensuses, March quarter. IMPV reported a revenue of $44.8m (well above $40.5m consensus), and a loss of $0.26 per share was smaller than the $0.38 loss expected. IMPV raised their June quarter consensus to $47-$49m and (0.20) to (0.24), which is... More

Oppenheimer Raises PT After Imperva's (IMPV) Strong 1Q Showing

May 8, 2015 6:38 AM EDT

Oppenheimer reiterates their Outperform rating on Imperva, Inc. (NYSE: IMPV), and raised their price target to $58 (from $55), after a strong 1Q15.IMPV reported revenue up 42% YoY to $44.8M, which bested Oppenheimer estimates of $40.5M. IMPV also reported a loss per share of $0.26, better than estimated... More

Imperva (IMPV) Tops Q1 EPS by 12c; Guides FY15

May 7, 2015 5:09 PM EDT

Imperva (NYSE: IMPV) reported Q1 EPS of ($0.26), $0.12 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $44.8 million versus the consensus estimate of $40.5 million.

Imperva sees FY2015 EPS of ($0.77)-($0.63), versus the consensus of ($0.85). Imperva sees FY2015 revenue of $202-207... More